Viking Global Investors
GRCL

Viking Global Investors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Viking Global Investors’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-491,647
Closed -$2.97M – 118
2021
Q4 		$2.97M Sell
491,647
-866,212
-64% -$8.33M 0.01% 107
2021
Q3 		$18.8M Buy
1,357,859
+27,531
+2% +$325K 0.05% 93
2021
Q2 		$17.3M Sell
1,330,328
-14,748
-1% -$197K 0.05% 86
2021
Q1 		$20.7M Buy
+1,345,076
New +$31.7M 0.06% 86

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Viking Global Investors's GRCL Position: Q1 2022 in Review

Viking Global Investors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2022, closing a stake of 491,647 shares — an estimated $2.97M sold.

Viking Global Investors first reported a position in GRCL in Q1 2021 and held it in 4 quarters. The position peaked at $20.7M in Q1 2021. 34 funds tracked by Wall St. Rank hold GRCL as of Q1 2022.

  • Viking Global Investors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Viking Global Investors sold 491,647 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2022, an estimated $2.97M.
  • Viking Global Investors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 4 quarters.
  • Viking Global Investors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $20.7M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2022.

Based on Viking Global Investors's 13F filing for Q1 2022, filed 16 May 2022.